Kojin Therapeutics, founded with a mission to develop innovative treatments for diseases traditionally deemed intractable, focuses on harnessing groundbreaking discoveries in cell-state and ferroptosis biology. The company offers first-in-class therapies aimed at treating various forms of cancer, cardiovascular, immunologic, hepatic, and degenerative diseases. Kojin's drug-discovery platform integrates computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to create novel therapeutics.

Notable figures affiliated with Kojin Therapeutics include leading scientists and industry experts who have contributed significantly to the fields of cell biology and drug discovery. The company has attracted investments from prominent venture capital firms, underscoring confidence in its innovative approach. Kojin's key achievements include the successful development of a robust drug-discovery platform and the advancement of several promising therapeutic candidates. Overall, Kojin Therapeutics is making a substantial impact by pioneering new treatment paradigms for challenging diseases.